Subscribe To
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
– Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – – ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 – ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies […] The post Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting ap...
Read More
Posted: Oct 16 2023, 11:05
Author Name: forextv
Views: 112444